Andrew Booth - Jun 7, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Financial Officer
Signature: /s/ Tryn Stimart, attorney-in-fact
Stock symbol: ABCL
Transactions as of: Jun 7, 2021
Transactions value $: $306,000
Form type: 4
Date filed: 6/9/2021, 08:30 PM
Next filing: Jun 10, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership
transaction	ABCL	Common Shares	Options Exercise	$114K	+600K		$0.19^*	600K	Jun 7, 2021	Direct
transaction	ABCL	Common Shares	Options Exercise	$192K	+600K	+100%	$0.32^*	1.2M	Jun 7, 2021	Direct
holding	ABCL	Common Shares						117K	Jun 7, 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-600K	-66.67%	$0.00	300K	Jun 7, 2021	Common Shares	600K	$0.19	Direct	F1
transaction	ABCL	Share Option (right to buy)	Options Exercise	$0	-600K	-10.81%	$0.00	4.95M	Jun 7, 2021	Common Shares	600K	$0.32	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2	2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Content

The shares subject to such option vest and become exercisable annually in equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

2,000,000 shares subject to the option vested and became exercisable on March 23, 2020. The remaining 3,550,000 shares (the "Remaining Shares") subject to the option vest and become exercisable as follows: 25% of the Remaining Shares subject to such option vested and became exercisable on August 22, 2020 and the remainder of the Remaining Shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.